Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GPBAR1 | Q8TDU6 | 6/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30564320 | 0.81 | HSD17B10 (0.69) | HSD17B10ALDH1A1TSHRSMN1; SMN2GAA | |
| SCHEMBL2360248 | 0.81 | HSD17B10 (0.69) | HSD17B10ALDH1A1TSHRSMN1; SMN2GAA | |
| SCHEMBL27350487 | 0.81 | ALDH1A1 (0.48) | ALDH1A1MAPTGPBAR1SMN1; SMN2MAOA | |
| SCHEMBL28763126 | 0.81 | ALDH1A1 (0.48) | ALDH1A1MAPTSMN1; SMN2GAAMAOA | |
| SCHEMBL12098050 | 0.79 | HTT (0.48) | ALDH1A1MAPTGPBAR1SMN1; SMN2GAA | |
| SCHEMBL29973546 | 0.78 | ALDH1A1 (0.61) | ALDH1A1MAPTHTT | |
| SCHEMBL20189898 | 0.78 | ALDH1A1 (0.61) | ALDH1A1MAPTHTT | |
| SCHEMBL319113 | 0.77 | HSD17B10 (0.52) | HSD17B10ALDH1A1MAPTTSHRSMN1; SMN2 | |
| SCHEMBL19721401 | 0.77 | GRM4 (0.49) | GPBAR1TSHRSMN1; SMN2MAOAMAOB | |
| SCHEMBL28913472 | 0.75 | ALDH1A1 (0.49) | ALDH1A1MAPTGAAHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385022-B2 | 3-amino-pyridines as GPBAR1 agonists | HOFFMANN-LA ROCHE INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-20150152058-A1 | 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS | HOFFMANN-LA ROCHE INC. | 2015-06-04 | — | — | US | disclosed |
| CN-101679266-B | PIM kinase inhibitors and methods of their use | NOVARTIS AG | 2015-05-06 | — | — | CN | disclosed |
| EP-2681194-B1 | 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS | HOFFMANN LA ROCHE (CH) | 2015-04-15 | — | — | EP | disclosed |
| US-8987307-B2 | 3-amino-pyridines as GPBAR1 agonists | HOFFMANN-LA ROCHE INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-8822497-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| US-8822497-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| EP-2132177-B1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-20120232051-A1 | 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS | HOFFMANN-LA ROCHE INC. | 2012-09-13 | — | — | US | disclosed |
| WO-2012117000-A1 | 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-07 | — | — | WO | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| CN-101679266-A | PIM kinase inhibitors and methods of their use | NOVARTIS AG | 2010-03-24 | — | — | CN | disclosed |
| EP-2132177-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis Ag (CH) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008106692-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008106692-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385022-B2 | 3-amino-pyridines as GPBAR1 agonists | GPBAR1, ADRA1B, GPR119 | HSD17B10 2580/4885ALDH1A1 446/4885MAPT 3894/4885 |
| US-20120232051-A1 | 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS | GPBAR1, ADRA1B, GPR119 | HSD17B10 2580/4885ALDH1A1 446/4885MAPT 3894/4885 |
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | HSD17B10 4209/4885ALDH1A1 2176/4885MAPT 4106/4885 |
| US-20150152058-A1 | 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS | GPBAR1, ADRA1B, GPR119 | HSD17B10 2580/4885ALDH1A1 446/4885MAPT 3894/4885 |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | HSD17B10 4209/4885ALDH1A1 2176/4885MAPT 4106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.